On the last day 5, The New England Journal of Medicine published a groundbreaking study in the fight against cancer. This is because scientists at the Memorial Sloan-Kettering Cancer Center in New York, USA, developed an experimental drug with complete success while searching for new treatments for this disease.

The drug has proven to be 100% effective in a US study. Photo: Freepik/Disclosure

The drug was able to eliminate colon tumors in all patients included in the small group evaluated. Twelve people with advanced rectal adenocarcinoma and a rare mutation received the drug for six months.

According to the study, the so-called “dostarlimab” meant that after follow-up, all 12 patients had “complete clinical response, with no evidence of tumor on MRI, fluorodeoxyglucose positron emission tomography, endoscopy, digital rectal examination, or biopsy.” .

The drug promises to “expose” cancer cells, so that the patient’s immune system is able to completely destroy them.

The drug can completely destroy cancer cells – Photo: Geraldo Bubniak/AEN

cost of treatment

Each dose of dostarlimab costs about US$11,000, the equivalent of about R$55,000, according to The New York Times. The development is funded by the British pharmaceutical company GlaxoSmithKline, the Simon and Eva Colin Foundation, the non-profit organization Swim Across America, the Stand Up to Cancer program and the US National Cancer Foundation.

In an interview with the journal, the lead author of the study, Luis Diaz, noted the results: “I believe this is the first time that [uma resposta de 100%] happens in the history of cancer.”